ZS Pharma, Inc. et al v. Lupin Limited et al
ZS Pharma, Inc. and AstraZeneca Pharmaceuticals LP |
Lupin Limited and Lupin Pharmaceuticals, Inc. |
1:2022cv01055 |
August 10, 2022 |
US District Court for the District of Delaware |
Vacant Judgeship (2022) |
Gregory B Williams |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 Patent Infringement |
None |
Docket Report
This docket was last retrieved on October 7, 2022. A more recent docket listing may be available from PACER.
Document Text |
---|
Filing 19 ANSWER to Amended Complaint, re: #16 Amended Complaint Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Lupin Pharmaceuticals, Inc., Lupin Limited.(Bilson, David) |
Filing 18 ORAL ORDER IT IS HEREBY ORDERED that, not later than thirty (30) days from the date of this Order, the parties shall meet and confer and file a joint proposed Scheduling Order in this action consistent with the applicable form Scheduling Order of Judge Williams, which is posted at http://www/ded/uscourts.gov (see Chambers, Judge Williams, Forms), along with a cover letter requesting the Court to enter the joint proposed Scheduling Order (if there are no disputes or other issues concerning scheduling that the Court needs to address) or to schedule the Scheduling Conference. If there are disputes or other issues the Court needs to address in the joint proposed Scheduling Order, in the cover letter, the parties shall direct the Court to the paragraph numbers in the joint proposed Scheduling Order which those appear. ORDERED by Judge Gregory B. Williams on 10/4/22. Associated Cases: 1:22-cv-01101-GBW, 1:22-cv-01055-GBW, 1:22-cv-01099-GBW (ntl) |
Filing 17 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,406,662 REVISED. (Silver, Daniel) |
Filing 16 First AMENDED COMPLAINT for Patent Infringement against Lupin Limited, Lupin Pharmaceuticals, Inc.- filed by ZS Pharma, Inc., AstraZeneca Pharmaceuticals LP. (Attachments: #1 Exhibit A-M)(Silver, Daniel) |
Pro Hac Vice Attorney James Y. Li for AstraZeneca Pharmaceuticals LP and ZS Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:22-cv-01055-GBW, 1:22-cv-01096-GBW, 1:22-cv-01099-GBW, 1:22-cv-01100-GBW, 1:22-cv-01101-GBW(mpb) |
Pro Hac Vice Attorney Alison M. King for Lupin Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) |
Case Reassigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb) |
Pro Hac Vice Attorney Kurt A. Mathas for Lupin Limited and for Lupin Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (smg) |
Filing 15 MOTION for Pro Hac Vice Appearance of Attorney Kurt A. Mathas, Alison M. King and Claire A. Fundakowski - filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Attachments: #1 Certification of Kurt A. Mathas, #2 Certification of Alison M. King, #3 Certification of Claire A. Fundakowski)(Bilson, David) |
SO ORDERED, re #15 MOTION for Pro Hac Vice Appearance of Attorney Kurt A. Mathas, Alison M. King and Claire A. Fundakowski filed by Lupin Limited, Lupin Pharmaceuticals, Inc. ORDERED by Judge Colm F. Connolly on 9/6/22. (ntl) |
Filing 14 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited for Lupin Pharmaceuticals, Inc. filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Phillips, John) |
Filing 13 ANSWER to #1 Complaint, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Lupin Pharmaceuticals, Inc., Lupin Limited.(Phillips, John) |
Pro Hac Vice Attorney Hassen Sayeed and Daniel O'Boyle for AstraZeneca Pharmaceuticals LP and ZS Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Related Cases: 1:22-cv-01101-VAC, 1:22-cv-01096-VAC, 1:22-cv-01099-VAC, and 1:22-cv-01100-VAC. (mkr) |
SO ORDERED re (13 in 1:22-cv-01101-VAC, 15 in 1:22-cv-01100-VAC, 12 in 1:22-cv-01055-VAC, 11 in 1:22-cv-01099-VAC, 11 in 1:22-cv-01096-VAC) MOTION for Pro Hac Vice Appearance of Attorney Hassen Sayeed, Daniel O'Boyle, and James Li filed by AstraZeneca Pharmaecuticals LP, AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc. ORDERED by Judge Maryellen Noreika on 8/31/2022. (dlw) |
Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Hassen Sayeed, Daniel O'Boyle, and James Li - filed by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc., AstraZeneca Pharmaecuticals LP. (Attachments: #1 Certifications for Hassen Sayeed, Daniel O'Boyle, and James Li)(Silver, Daniel) |
Filing 11 NOTICE of Appearance of Lisa B. Pensabene by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc., AstraZeneca Pharmaecuticals LP (Silver, Daniel) |
Filing 10 Return of Service Executed by ZS Pharma, Inc., AstraZeneca Pharmaceuticals LP. Lupin Pharmaceuticals, Inc. served on 8/12/2022, answer due 9/2/2022. (Joyce, Alexandra) |
Filing 9 DECLARATION of Service for Lupin Limited by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc.. (Attachments: #1 Exhibit A-B)(Joyce, Alexandra) |
Filing 8 VAC Notice, Consent, Non-Consent, Magistrate Referral (ntl) |
Filing 7 ORAL ORDER: This case has been assigned to the District of Delaware's Vacant Judgeship ("VAC"). Detailed information relating to VAC cases may be found in the Court's Announcement of March 3, 2022 and Standing Order No. 2022-VAC-1 (March 9, 2022), which are found on the Court's website. Consistent with the foregoing Announcement and Standing Order, IT IS HEREBY ORDERED that the parties shall file the "Notice of Consent or Absence of Consent to Proceed Before a United States Magistrate Judge," being docketed along with the instant order, no later than sixty (60) days after service of the Complaint on the first defendant that is served. IT IS FURTHER ORDERED that the Notice, Consent, and Referral forms re: U.S. Magistrate Judge jurisdiction, previously docketed in this case, are VACATED. Issued by the Clerk of Court on 8/17/2022. (ntl) |
Case Assigned to Vacant Judgeship (2022). Please include initials of VAC after the case number on all documents filed. (rjb) |
Filing 6 Summons Issued as to Lupin Limited on 8/11/2022; Lupin Pharmaceuticals, Inc. on 8/11/2022. (Attachments: #1 Summons Issued)(lam) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC, for ZS Pharma, Inc. filed by ZS Pharma, Inc and AstraZeneca Pharmaceuticals LP (lam) Modified on 8/11/2022 (lam). |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attachment. (Attachments: #1 Patent/Trademark Report 2, #2 Patent/Trademark Report 3)(lam) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than July 1, 2022. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 11/18/2025. (lam) Modified on 8/11/2022 (lam). |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) |
Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Lupin Limited and Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-3934701.) - filed by ZS Pharma, Inc and AstraZeneca Pharmaceuticals LP (Attachments: #1 Exhibit A-L, #2 Civil Cover Sheet)(lam) Modified on 8/11/2022 (lam). |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.